Eight-Week Cabotegravir Injection Has HIV PrEP Potential
Interim analysis shows a long-acting injectable was associated with fewer HIV infections than daily oral PrEP in a diverse population of HIV-risk participants.
A long-acting injectable pre-exposure prophylaxis (PrEP) option may allow person at risk of HIV infection to administer preventive care with one shot every 2 months, according to new clinical findings.
In interim analysis from a randomized, double-blind trial presented at the International AIDS Society (IAS) AIDS 2020 Virtual Sessions this week, investigators reported that eight-week, injected, investigational novel integrase inhibitor cabotegravir reported three-fold fewer HIV infections among participants than those who were administered standard daily oral PrEP (Truvada).
Results from the trial, conducted by the clinical collaborative HIV Prevention Trials Network, involved approximately 4600 cisgender men and transgender women who have sex with men, from 43 sites across 7 countries. The trial was anticipated to continue into 2022, but was halted in May following the highly effective interim results for cabotegravir.
Investigators compared eight-week injectable cabotegravir PrEP to an equivalent placebo, plus either standard daily oral PrEP or an equivalent placebo.
ViiV Healthcare, sponsoring organizer of the trial, additionally set mandates to assure a very diverse patient population—at least half of participants were black men who have sex with men, the leading population of HIV-infected patients in the US.
Another two-thirds of participants were <30 years old, and 12% were transgender women.
Supplemental to the primary outcome of preventing HIV infection in at-risk patients, investigators considered participant adherence to their given method of PrEP—consistent administration of a daily oral pill has been a continued struggle for the HIV-risk community.
The team found in blood analyses, in a subset of 372 patients administered daily oral PrEP pills, just three-fourths adhered to the scheduled regimen. Overall, 13 participants to receive long-acting injectable cabotegravir reported an HIV infection at trial’s end—compared to the 39 who were given daily oral PrEP.
In a statement provided to a report by the New York Times, Kimberly Smith, MD, MPH, head of research and development at ViiV, said the company now anticipates filing for US Food and Drug Administration (FDA) approval for cabotegravir as an injectable PrEP option in early 2021.